Dopamine inhibits Na',K+-ATPase activity in several renal tubule segments and thereby regulates urinary Na" excretion. We now show that a phosphopeptide of 31 amino acids, corresponding to residues 8-38 of the protein phosphatase inhibitor DARPP-32 (dopamine-and cAMPregulated phosphoprotein ofMr 32,000), mimics the inhibitory action of dopamine on Na',K+-ATPase activity in renal tubule cells from the ascending limb of the loop of Henle. The dephosphorylated form of the peptide Is ineffective. The results indicate that dopamine acts through a protein phosphorylation pathway to regulate the activity of an ion pump. In addition, the data suggest that inhibition of protein phosphatase 1 by phophorylated DARPl-32 is a component of the mechanism by which dopatine regulates urinary Na`excretion. Na+,K+-ATPase regulates a number of vital functions, including intracellular electrolyte homeostasis and pH, cell volume, membrane potential, cellular uptake of amino acids, and transcellular Na' transport (1). Na',K+-ATPase is particularly abundant in kidney and brain. Dopamine has been shown to inhibit the activity of this enzyme in neostriatal neurons (2) and in several segments of the rat renal nephron, including the proximal tubule (3, 4), the thick ascending limb (TAL) of the loop of Henle (5), and the cortical collecting tubule (6). The peripheral actions of dopamine are critical for the regulation of Na+ and extracellular volume homeostasis and for the regulation ofblood pressure (7). In fact, dopamine is the drug of choice in many clinical situations in which renal function is compromised. Therefore, an understanding of the cellular and molecular mechanisms by which dopamine regulates cellular Na' homeostasis is of interest both to cell biology and to clinical medicine.
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DARPP-32 (dopamine-and cAMP-regulated phosphoprotein of Mr 32,000) is localized to cells containing the D1 subclass of dopamine receptor, including medium-sized spiny neurons of the neostriatum (8) (9) (10) and renal tubule cells of the TAL (5) . (In this report we have used the terminology D1 and D2 to classify dopamine receptors. In the kidney, the functional equivalents of the D1 and D2 dopamine receptors are often referred to as the DA1 and DA2 receptors, respectively.) Phosphorylation ofDARPP-32 on threonine-34 converts it into a potent inhibitor (K-10-9M) (11) of protein phosphatase 1, a major protein phosphatase in virtually all tissues (12) . Although the biochemical mechanism of action of DARPP-32 has been established (11) , its precise physiological role in signal transduction is not yet understood. Distinct neurotransmitter pathways regulate the phosphorylation (13) and dephosphorylation (14) of DARPP-32. However, there has been no direct evidence that DARPP-32 mediates any of the actions of dopamine or other neurotransmitters that regulate its state of phosphorylation. In this study, we present evidence that phosphorylated DARPP-32 mimics D1 dopamine receptor agonists in inhibiting Na',K+-ATPase activity in renal tubule segments from the medullary TAL.
MATERIALS AND METHODS
Synthesis and Phosphorylation of Dephospho-DARPP-32-(8 38) Fragent. The 31-residue peptide Lys-Ile-Gln-Phe-SerVal-Pro-Ala-Pro-Pro-Ser-Gln-Leu-Asp-Pro-Arg-Gln-Val-GluMet-Ile-Arg-Arg-Arg-Arg-Pro-Thr-Pro-Ala-Met-Leu [dephospho-DARPP-32-(8-38)] was synthesized by the solid-phase method using a model 430A Applied Biosystems peptide synthesizer and was purified by reverse-phase HPLC as described (15) . The catalytic subunit of cAMP-dependent protein kinase was purified from bovine heart as described (16) . The peptide was phosphorylated on threonine-34 by incubation with cAMP-dependent protein kinase at 300C in a reaction volume of 1 ml containing (final concentrations) 50 mM Hepes (pH 7.4), 1 mM EGTA, 10 mM magnesium acetate, 1-6 mM ATP, 4-20 ,ug of the catalytic subunit of cAMPdependent protein kinase, and 1-4 mM dephospho-DARPP-32-(8-38). The reaction was terminated after 6 hr by the addition of 0. tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. NaCi, 5 mM KCI, 0.8 mM MgSO4, 0.33 mM Na2HPO4, 0.44 mM KH2PO4, 0.25 mM CaCl2, 1 mM MgCl2, and 10 mM Tris HCI (pH 7.4). After a 10-min incubation at room temperature, the tubule segments were washed several times in distilled H20 containing the peptide and then resuspended in physiological buffer in the absence of saponin. This procedure allowed fluorescent dextran molecules of Mr 4,000 and Mr 10,000 but not of Mr 16,000 to enter the cells. Upon changing the medium, fluorescent dextran molecules of Mr 4,000 and Mr 10,000 remained in the cells. When higher concentrations of saponin were used to permit larger molecules to enter the cells, the dextran molecules were found to leave the cells upon changing the medium.
Measurement of Na',K+-ATPase Activity. Segments were subjected to rapid cold shock to permeabilize the tubule cells. Na+,K+-ATPase activity was measured as described (4) Kinetic analyses were carried out as described (17) . When the concentration of K+ was varied, Na+ was held constant at 70 mM. When the concentration of Na+ was varied, K+ was held constant at 5 mM.
Na+,K+-ATPase was partially purified from homogenized rat kidney by the method of Jorgensen (18) . The activity of the enzyme (expressed here as pmol of ATP hydrolyzed per mg of protein per hr) was 803 + 263 (n = 4) in the presence of 10 AM dephospho-DARPP-32-(8-38) and 719 ± 182 (n = 4) in the presence of 10 AM phospho-DARPP-32-(8-38).
RESULTS
A phosphopeptide of 31 amino acids corresponding to residues 8-38 of DARPP-32, designated phospho-DARPP-32-(8-38), was used for these studies. Renal tubule segments were permeabilized with saponin to test the possibility that phospho-DARPP-32 inhibits Na+,K+-ATPase activity. Phospho-DARPP-32-(8-38) was sufficiently small to penetrate the plasma membrane of the saponin-treated cells, yet large enough to retain potency as an inhibitor of protein phosphatase 1 (see Materials and Methods). Dephospho-DARPP-32-(8-38), which like dephospho-DARPP-32 has no potency as an inhibitor of protein phosphatase 1, was used for comparison.
The effects of various concentrations of phospho-DARPP-32-(8-38) and dephospho-DARPP-32-(8-38) on Na+,K+-ATPase activity are compared in Fig. 1 . Phospho-DARPP-32-(8-38), but not dephospho-DARPP-32-(8-38), inhibited Na+,K+-ATPase activity, 90% inhibition being observed at 100 ,uM phospho-DARPP-32-(8-38). The concentrations of phospho-DARPP-32-(8-38) required to inhibit Na+,K+-ATPase activity of the tubule cells were considerably higher than the IC50 (40 nM) determined with purified protein phosphatase 1c. This difference may be attributable to one or more of the following: (i) adsorption of the peptide to extracellular components ofthe tissue, (ii) limited amounts of the peptide entering the cells, (iii) high concentration of protein phosphatase 1 in most mammalian cells (estimated to be 0.5-1 ,M), (iv) intracellular dephosphorylation of the peptide, and (v) intracellular proteolysis of the peptide.
The inhibition (45%) observed in the presence of 10 ,uM phospho-DARPP-32-(8-38) was comparable to that observed with maximally effective concentrations of the D1 agonist SKF 82526 (35% at 0.1,M) or of dibutyryl-cAMP (42% at 10 mM) (data not shown). The dopamine-induced inhibition of Na+,K+-ATPase activity in the tubule cells of the TAL is mimicked by selective D1 agonists (4). In contrast, the dopamine-induced inhibition of Na+,K+-ATPase activity of medium-spiny neurons from the neostriatum (2) and of renal cells from the proximal convoluted tubule (19) It seems unlikely that the inhibitory effect of phospho-DARPP-32-(8-38) on the Na+,K+-ATPase activity of the tubule cells is attributable to a nonspecific action in view of the lack of effect of dephospho-DARPP-32-(8-38). A direct effect on the Na+,K+-ATPase is also unlikely since neither phospho-DARPP-32-(8-38) nor dephospho-DARPP-32-(8-38) at concentrations of 10 ,uM or 100 ,uM had any effect on the activity of partially purified Na+,K+-ATPase from rat kidney (data not shown). The results are consistent with the idea that phospho-DARPP-32-(8-38) produced its effect by virtue of inhibiting endogenous protein phosphatase 1.
Protein phosphatase 1 is one of the major protein phosphatases in virtually all cells and tissues (12) . Phospho-DARPP-32-(8-38) would be expected to have effects on all phosphoproteins that are subject to regulation by protein phosphatase 1 in DARPP-32-containing cells. Compatible with this idea, 100 1LM phospho-DARPP-32-(8-38) inhibited ouabain-insensitive ATPase activity in renal tubule cells (Fig.  3) , suggesting that other ion pumps are also regulated by protein phosphatase 1. The difference in sensitivity of the Na',K+-ATPase activity and the ouabain-insensitive ATPase activity to inhibition by phospho-DARPP-32- is not yet understood but may provide a clue to the molecular steps between protein phosphatase 1 and these distinct ion pumps.
DISCUSSION
The level of active Na' transport in the ascending limb of the loop of Henle influences net urinary Na' excretion and the concentration of urine. Therefore, disturbances of extracellular volume and tonicity can be adjusted by regulation of Na',K+-ATPase activity in the TAL. Our data suggest that inhibition of protein phosphatase 1 activity by phospho-DARPP-32 is one of the mechanisms by which these vital parameters are regulated. Medullary TAL cells have one of the highest levels of Na',K+-ATPase activity found in any mammalian tissue (20) . The Na' gradient created by Na',K+-ATPase-mediated transcellular Na+ transport in the water-impermeable medullary TAL segment of the nephron is an extremely energy-demanding process (21) . In situations of shock and hypoxia, down-regulation of this process is necessary to prevent permanent damage to the medullary TAL cells (22) . Therefore, a physiological pathway responsible for regulation of Na+,K+-ATPase activity in medullary TAL cells has long been sought. A hypothetical scheme by which dopamine and DARPP-32 might be involved in regulation of Na',K+-ATPase activity is presented in Fig. 4 . It will be important to determine the identity of the substrate(s) for the protein phosphatase 1/DARPP-32 system that is involved in the regulation of Na',K+-ATPase activity. The simplest explanation for the inhibition by phospho-DARPP-32 of Na',K+-ATPase activity is that phospho-DARPP-32 inhibits the dephosphorylation of the pump itself by protein phosphatase 1. However, it is also possible that phospho-DARPP-32 acts by inhibiting the dephosphorylation of a modulator of Na',K+-ATPase. Fur- ther experiments using reconstituted systems should clarify these issues.
